The year’s merger-and-acquisition trend continues. Today, the last day of January, Bothell, Washington-based?Seattle Genetics?announced?it is buying Seattle-based?Cascadian Therapeutics?for about $614 million.
Clinical Phase Biopharmaceuticals company Cascadian Therapeutics today announced a review of recent advances in tucatinib, an investigational oral small molecule kinase inhibitor